ROZLYTREK is a tyrosine kinase inhibitor with a well-tolerated and consistent safety profile in both adult and paediatric patients^1,2

Therapeutic indications¹

ROZLYTREK as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older, with solid tumours, expressing a NTRK gene fusion: 

• who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and

• who have not received a prior NTRK inhibitor,

• who have no satisfactory treatment options.

ROZLYTREK as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced NSCLC not previously treated with ROS1 inhibitors.